Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
出版年份 2017 全文链接
标题
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 11, Pages -
出版商
Oxford University Press (OUP)
发表日期
2017-03-17
DOI
10.1093/jnci/djx066
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
- (2017) David Miles et al. EUROPEAN JOURNAL OF CANCER
- Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
- (2016) Cong Zhou et al. BRITISH JOURNAL OF CANCER
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue
- (2016) Koen M. Marien et al. PLoS One
- Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab
- (2015) Wei Wei et al. MOLECULAR CANCER THERAPEUTICS
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
- (2014) A. Backen et al. CLINICAL CANCER RESEARCH
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
- (2013) F. Collinson et al. CLINICAL CANCER RESEARCH
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
- (2013) M. J. Brauer et al. CLINICAL CANCER RESEARCH
- Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?
- (2013) J. H. McCarty CLINICAL CANCER RESEARCH
- Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab
- (2013) L. Randall et al. GYNECOLOGIC ONCOLOGY
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Developmental and Pathological Angiogenesis
- (2011) Alicia S. Chung et al. Annual Review of Cell and Developmental Biology
- Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
- (2011) A. M. Jubb et al. CLINICAL CANCER RESEARCH
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action
- (2010) Napoleone Ferrara MOLECULAR BIOLOGY OF THE CELL
- Immunohistochemistry in the evaluation of neovascularization in tumor xenografts
- (2008) D Wang et al. BIOTECHNIC & HISTOCHEMISTRY
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
- (2008) J. Ma et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started